Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381348 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL30673511 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29725684 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29403553 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL30067164 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL30678552 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL24632196 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL2624852 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29330492 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL13663954 | 1.00 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023221797-A9 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-02-13 | — | — | WO | disclosed |